In this study, we demonstrated that azelnidipine could dual target SIRPα and PVR, simultaneously block the negative signal pathway, enhance the phagocytosis of tumor cells by macrophages, and significantly inhibit tumor growth. The gene discussed is PVR; the disease is neoplasm.